WALTHAM, Mass.--(BUSINESS WIRE)--OvaScienceSM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, today announced that it has finalized its commercial agreement with the IVF JAPAN GROUP and that the AUGMENTSM treatment is now available to women through the clinic. The AUGMENT treatment is designed to improve the health of a woman’s existing eggs and enhance in-vitro fertilization (IVF) procedures. The commercial agreement follows a non-commercial preceptorship training program at IVF JAPAN GROUP, which was approved by the Japan Society of Obstetrics and Gynecology (JSOG).
“Each year in Japan, hundreds of thousands of women and couples seek infertility treatment and we believe that with the AUGMENT treatment, OvaScience is in a unique position to help,” said Harald F. Stock, Ph.D., President and Chief Executive Officer of OvaScience. “Feedback from clinicians and patients during the preceptorship program with IVF JAPAN GROUP was positive and there continues to be interest in and demand for our innovative technology in this strategically important region. The signing of this commercial agreement marks a milestone for OvaScience, as we continue to execute on our targeted expansion of the AUGMENT treatment. We look forward to a full commercial launch of AUGMENT in Japan in 2017, as we work to help women and couples build the families they deserve.”
Women’s infertility poses a significant issue for Japanese women and couples. Approximately, one in six couples have had fertility treatments.2 Further, Japanese men and women are marrying later in life, with the average age of first-time mothers rising above 30 years old.3 As such, the percentage of babies born using advanced reproductive assistance in Japan increased from 2.5% in 2009 to 4.1% in 2013.4,5 One of the causes of infertility is the high age of mothers, which is thought to have a significant impact on egg health and fertility rates.6 OvaScience estimates the Japanese market size for IVF alone to be approximately $3.2 billion.7
“At IVF JAPAN GROUP, we are committed to providing patients with the most advanced technologies available and are excited to offer the AUGMENT treatment,” said Yoshiharu Morimoto, M.D., Ph.D., Chief Executive Officer of IVF JAPAN GROUP. “For women with poor or compromised egg health, the rates of pregnancy success, even with IVF, are often low. The AUGMENT treatment represents a scientific advancement and can help patients by boosting the energy levels of their own eggs, a process that data suggest can promote embryo development and may increase IVF success rates. Our staff are well trained to offer this treatment more broadly as a promising new fertility option.”
During IVF, women often want to use their own eggs. However, many patients suffer with poor or compromised egg health, which can happen naturally with age or due to inherited reproductive disorders or other environmental or medical factors. The AUGMENT treatment is designed to improve egg health and enable women to use their own eggs with IVF by using energy-producing mitochondria from a woman’s own egg precursor (EggPCSM) cells to supplement existing mitochondria and revitalize her eggs. It is the first fertility treatment available to patients based on OvaScience’s proprietary EggPC cell technology.
The IVF JAPAN GROUP, a network that includes the IVF NAMBA CLINIC and the IVF OSAKA CLINIC will now offer AUGMENT commercially. For more information about the AUGMENT treatment in Japan, please visit www.ivfhorac.com and http://www.augmenttreatment.com/ja.
The AUGMENT treatment is not available in the United States.
OvaScience (NASDAQ:OVAS) is a global fertility company dedicated to improving treatment options for women around the world. OvaScience is discovering, developing and commercializing new fertility treatments because we believe women deserve more options. Each OvaScience treatment is based on the Company’s proprietary technology platform that leverages the breakthrough discovery of egg precursor (EggPC) cells – immature egg cells found inside the protective ovarian lining. The AUGMENT treatment, a fertility option specifically designed to improve egg health, is available in certain IVF clinics in select international regions. OvaScience has commenced a preceptorship program with the OvaPrimeSM treatment, which could increase a woman’s egg reserve, and is developing the OvaTureSM treatment, a potential next-generation IVF treatment that could help a woman produce healthy, young, fertilizable eggs without hormone injections. OvaScience treatments are not available in the United States. For more information, please visit www.ovascience.com and www.augmenttreatment.com and connect with us on Twitter and Facebook.
This press release includes forward-looking statements about the Company's plans for the AUGMENT treatment, including statements relating to plans to expand access to AUGMENT in Japan and plans for a full commercial launch of AUGMENT in Japan beginning in 2017. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: the possibility that international IVF clinics that we work with may determine not to provide or continue providing the AUGMENT treatment, or to delay providing such treatments, based on clinical efficacy, safety or commercial, logistic, regulatory or other reasons; the science underlying our treatments (including the AUGMENT, OvaPrime and OvaTure treatments), which is unproven; our ability to obtain regulatory approval or licenses where necessary for our treatments; our ability to develop our treatments on the timelines we expect, if at all; our ability to commercialize our treatments, on the timelines we expect, if at all; as well as those risks more fully discussed in the "Risk Factors" section of our most recently filed Quarterly Report on Form 10-Q and/or Annual Report on Form 10-K. The forward-looking statements contained in this press release reflect our current views with respect to future events. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our view as of any date subsequent to the date hereof.
1 Japan Society of Obstetrics and Gynecology ART Databook
2 National Institute of Population and Security Research Survey No. 14, 2010, (http://www.ipss.go.jp/ps-doukou/j/doukou14/chapter4.html, p11)
3 Ministry of Health, Labour and Welfare, Report of Vital Statistics 2014 (http://www.mhlw.go.jp/toukei/saikin/hw/jinkou/geppo/nengai14/dl/gaikyou26.pdf, p4
4 Japan Society of Obstetrics and Gynecology ART Databook 2013, (http://plaza.umin.ac.jp/~jsog-art/2013data.pdf, p2)
5 Ministry of Health, Labour and Welfare, Report of Vital Statistics 2014, (http://www.mhlw.go.jp/toukei/saikin/hw/jinkou/kakutei14/dl/04_h2-1.pdf, p5)
6 “Female age-related fertility decline,” American Society For Reproductive Medicine, March 2014, (https://www.asrm.org/uploadedFiles/ASRM_Content/News_and_Publications/Practice_Guidelines/Committee_Opinions/Age-related_fertility.pdf, p.1)
7 Allied Market Research report, 2014 https://www.alliedmarketresearch.com/asia-pacific-in-vitro-fertilization-market